Cancer breakthrough for thousands as test could tell if blood cancer medicine will work
Performed under local anaesthetic, the gene test could help identify patients with myeloma that will benefit from treatment known as lenalidomide. (Source: Daily Express - Health)
Source: Daily Express - Health - March 19, 2023 Category: Consumer Health News Source Type: news
Natco Pharma launches additional strengths of generic version of Revlimid in US
Natco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multiple myeloma, in the US. The company has launched 2. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 10, 2023 Category: Pharmaceuticals Source Type: news
Mayo Clinic Minute: What is multiple myeloma?
Multiple myeloma is a relatively uncommon form of blood cancer that affects less than 1% of the U.S. population, according the American Cancer Society. March is Myeloma Awareness Month. People younger than 45 rarely get the disease, and it occurs more in older men than women. And your risk is doubled if you're African American. Watch: The Mayo Clinic Minute https://youtu.be/pShHvj3Y3Nw Journalists: Broadcast-quality video (1:06) is in the downloads at the end of this post.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 10, 2023 Category: Databases & Libraries Source Type: news
Rangaswamy Govindarajan Named Chief of UAMS Hematology, Oncology
He'll lead a team of physicians treating patients with benign and malignant hematological disorders, multiple myeloma and solid tumors. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - March 8, 2023 Category: American Health Source Type: news
Janssen Launches Health Equity Campaign in Partnership with Award-Winning Radio Host D.L. Hughley to Raise Awareness About Multiple Myeloma Among Black Communities
HORSHAM, P.A., March 2, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the launch of That’s My Word™ to raise awareness of and help to drive better health outcomes for multiple myeloma among at-risk populations. A national campaign bringing together trusted voices among Black communities, including those at risk of multiple myeloma, care partners, healthcare professionals, advocacy groups and award-winning radio host and comedian D.L. Hughley, That’s My Word™ aims to be a source of both information and hope by sharing resources specifically for Black patients and their care p...
Source: Johnson and Johnson - March 2, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Hope For Universal, Ready-Made CAR T Therapy For Multiple Myeloma
A clinical trial released encouraging safety results for a universal, ready-made version of CAR T therapy for multiple myeloma. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 23, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
Pfizer's elranatamab receives FDA and EMA filing acceptance
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company's Biologics License Application (BLA) for elranatamab, an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody (BsAb), for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). (Source: World Pharma News)
Source: World Pharma News - February 22, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Africa: Why Has the Price of This Cancer Medicine Risen and Fallen By Over a Thousand Percent Since 2016?
[spotlight] Lenalidomide is an important medicine used for the treatment of multiple myeloma - a type of bone marrow cancer that is not curable and typically requires long-term, ongoing treatment. Lenalidomide, however, is perhaps most infamous for its high price tag. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 17, 2023 Category: African Health Source Type: news
Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
CAR-T Makes Its Case for Earlier Use in Multiple Myeloma
(MedPage Today) -- Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel; Abecma) significantly improved outcomes in patients with triple-class-exposed, relapsed and refractory multiple myeloma, according to the phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 11, 2023 Category: Hematology Source Type: news
Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma
FRIDAY, Feb. 10, 2023 -- For patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, prolongs progression-free survival and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 10, 2023 Category: Pharmaceuticals Source Type: news
Miami Cancer Institute to host cancer experts at Fourth Annual Global Summit on Immunotherapies for Hematologic Malignancies
Miami Cancer Institute, part of Baptist Health, announced the Fourth Annual Global Summit on Immunotherapies for Hematologic Malignancies, to be held March 10-11, 2023, at the Ritz-Carlton Hotel in Coconut Grove, Miami, Florida. The educational summit has been designed to provide an overview of the most recent advances in the treatment of leukemia, lymphoma, multiple myeloma and stem cell transplantation through novel immunotherapies and treatment combinations. In addition, updates on evolving immunologically … (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 10, 2023 Category: Pharmaceuticals Authors: Baptist Health Source Type: news
Novel 'Off the Shelf' CAR-T Product Shows Promise in Myeloma
(MedPage Today) -- Use of an allogeneic B-cell maturation antigen (BCMA)-targeting CAR T-cell therapy was feasible and safe and induced responses in patients with relapsed or refractory multiple myeloma, according to interim results from the phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 3, 2023 Category: Hematology Source Type: news
Alternative to Lenalidomide ID'd for Maintenance in Multiple Myeloma
WEDNESDAY, Feb. 1, 2023 -- For patients with newly diagnosed multiple myeloma after induction treatment and autologous stem cell transplantation, maintenance therapy with carfilzomib, lenalidomide, and dexamethasone may be better than lenalidomide... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2023 Category: Pharmaceuticals Source Type: news
